BioCryst Pharmaceuticals Insiders Placed Bullish Bets Worth US$1.05m

When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase stock, like in BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) instance, it's good news for shareholders.

Although we don't think shareholders should simply follow insider transactions, we would consider it foolish to ignore insider transactions altogether.

See our latest analysis for BioCryst Pharmaceuticals

BioCryst Pharmaceuticals Insider Transactions Over The Last Year

In the last twelve months, the biggest single purchase by an insider was when Senior VP Anthony Doyle bought US$202k worth of shares at a price of US$5.57 per share. Even though the purchase was made at a significantly lower price than the recent price (US$8.15), we still think insider buying is a positive. Because the shares were purchased at a lower price, this particular buy doesn't tell us much about how insiders feel about the current share price.

In the last twelve months insiders purchased 183.60k shares for US$1.0m. But they sold 19.99k shares for US$123k. In the last twelve months there was more buying than selling by BioCryst Pharmaceuticals insiders. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!

BioCryst Pharmaceuticals is not the only stock that insiders are buying. For those who like to find small cap companies at attractive valuations, this free list of growing companies with recent insider purchasing, could be just the ticket.

Insiders At BioCryst Pharmaceuticals Have Sold Stock Recently

The last quarter saw substantial insider selling of BioCryst Pharmaceuticals shares. Specifically, Independent Director Amy McKee ditched US$54k worth of shares in that time, and we didn't record any purchases whatsoever. This may suggest that some insiders think that the shares are not cheap.

Insider Ownership Of BioCryst Pharmaceuticals

Many investors like to check how much of a company is owned by insiders. We usually like to see fairly high levels of insider ownership. BioCryst Pharmaceuticals insiders own about US$17m worth of shares. That equates to 1.0% of the company. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.

So What Does This Data Suggest About BioCryst Pharmaceuticals Insiders?

An insider sold stock recently, but they haven't been buying. On the other hand, the insider transactions over the last year are encouraging. We like that insiders own a fair amount of the company. So we're not overly bothered by recent selling. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing BioCryst Pharmaceuticals. For instance, we've identified 2 warning signs for BioCryst Pharmaceuticals (1 makes us a bit uncomfortable) you should be aware of.

Of course BioCryst Pharmaceuticals may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.